Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|July 27, 2022
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockersLaetitia Nebot-Bral, Antoine Hollebecque, Andrey A Yurchenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid TumorsJonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2022
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trialsPatricia Martin-Romano, Leo Colmet-Daage, Daphne Morel, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2022
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 studyMichele Maio, Mayur M Amonkar, Josephine M Norquist, et al.
JCO Precision Oncology|May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING TrialJulieta Rodriguez, Capucine Baldini, Arnaud Bayle, et al.
Cell Reports. Medicine|February 11, 2025
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancersStephane Champiat, Elena Garralda, Vladimir Galvao, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinomaGuru P Sonpavde, Cora N Sternberg, Yohann Loriot, et al.
The Journal of Clinical Investigation|May 20, 2014
Targeting CD137 enhances the efficacy of cetuximabHolbrook E Kohrt, A Dimitrios Colevas, Roch Houot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.
Pageof 7